{"organizations": [], "uuid": "a7ecd053d0485f43c45d736760be59a453a6ef51", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180202.html", "section_title": "Archive News &amp; Video for Friday, 02 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-tg-therapeutics-announces-updated/brief-tg-therapeutics-announces-updated-results-from-the-ongoing-phase-2-study-of-ublituximab-idUSFWN1PS10A", "country": "US", "domain_rank": 408, "title": "BRIEF-TG Therapeutics Announces Updated Results From The Ongoing Phase 2 Study Of Ublituximab", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-02-02T19:47:00.000+02:00", "replies_count": 0, "uuid": "a7ecd053d0485f43c45d736760be59a453a6ef51"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-tg-therapeutics-announces-updated/brief-tg-therapeutics-announces-updated-results-from-the-ongoing-phase-2-study-of-ublituximab-idUSFWN1PS10A", "ord_in_thread": 0, "title": "BRIEF-TG Therapeutics Announces Updated Results From The Ongoing Phase 2 Study Of Ublituximab", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "tg therapeutics inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 2 (Reuters) - Tg Therapeutics Inc:\n* TG THERAPEUTICS, INC. ANNOUNCES UPDATED RESULTS FROM THE ONGOING PHASE 2 STUDY OF UBLITUXIMAB (TG-1101) IN PATIENTS WITH MULTIPLE SCLEROSIS AT THE THIRD ANNUAL ACTRIMS FORUM 2018\n* TG THERAPEUTICS INC - TG-1101 WAS WELL TOLERATED ACROSS ALL PATIENTS INCLUDING THOSE RECEIVING 1 HOUR INFUSIONS AT PHASE 3 DOSE Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-02T19:47:00.000+02:00", "crawled": "2018-02-03T21:29:22.001+02:00", "highlightTitle": ""}